Navigation Links
Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
Date:9/26/2013

NEW HAVEN, Conn., Sept. 26, 2013 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form of equity, from the Connecticut Department of Economic and Community Development and Connecticut Innovations. Investors in the Series A round include co-leads Canaan Partners and 5AM Ventures along with Connecticut Innovations and Elm Street Ventures. The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.

Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell's own protein-degradation capabilities to bind to a particular protein and "label" it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins.  However, only 25 percent of the body's 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

"Degrading proteins as opposed to inhibiting them has potential to open up areas of drug development that were previously closed because of the technical limitations of protein inhibition," said Tim Shannon, MD, CEO of Arvinas and Venture Partner at Canaan Partners. "The Arvinas technology platform represents an entirely new class of drugs bringing an innovative approach to treating disease."

"In addition to the fact that a very large portion of proteins cannot be blocked, inhibition is not permanent, so a disease-causing protein can eventually become active again after treatment with a drug," said Dr. Crews. "To effectively stop cancer, a drug-binding site must be inhibited 95 percent of the time, which is currently difficult to achieve. If a protein is removed entirely, that should overcome this problem."

Arvinas also announced the formation of a Scientific Advisory Board (SAB), which will help guide the development of its novel approach. Members of the SAB include Daniel D. Von Hoff, MD, Chief, distinguished professor and director of clinical translational research division at the Translational Genomics Research Institute and Chief Scientific Officer for US Oncology; Mark Murcko, PhD, former Chief Technology Officer at Vertex Pharmaceuticals; Thomas J. Lynch, Jr., MD, Director of the Yale Cancer Center and Physician-in-chief at Smilow Cancer Hospital at Yale-New Haven;  Richard Ulevitch, Venture Partner 5AM  and Professor and  Chairman Emeritus of the Department of Immunology at The Scripps Research Institute, La Jolla, California; and Peter Farina, PhD, executive in residence at Canaan Partners and former Senior Vice-President of Development at Boehringer Ingelheim.

Arvinas worked with the Yale Office of Cooperative Research (OCR) to secure intellectual property protection for the technology.

"The Arvinas team has lined up an impressive slate of supporters of the unique technology that comes out of Yale University," noted John Soderstrom, PhD, Managing Director of the Office of Cooperative Research at Yale and a member of Arvinas' Board of Directors. "Degrading proteins that are driving disease has the potential to bring about drastic changes in drug development, and we anticipate significant interest from pharmaceutical companies."

Joining Dr. Shannon and Dr. Soderstrom on the Arvinas Board of Directors will be Kush Parmar, MD PhD and a Principal at 5AM Ventures and Brad Margus, the CEO of Genome Bridge and former CEO of Envoy Therapeutics.

About the Yale Office of Cooperative Research

The Yale Office of Cooperative Research works with faculty to realize the commercial potential of their discoveries through licensing of intellectual property, identification of opportunities to partner with corporate sponsors of research and facilitating the formation of new ventures based on Yale's intellectual property. Learn more at http://www.yale.edu/ocr.

About Arvinas

Arvinas Inc. is creating a new class of drugs based on protein degradation, which has the potential to open up areas of drug development that were previously closed because of the technical limitations of target inhibition. The company's technology is built on the research of Craig Crews, PhD of Yale University and has primary application in oncology indications as well as potential in inflammatory, autoimmune and rare diseases. http://www.arvinas.com/


'/>"/>
SOURCE Arvinas Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Predilytics Secures Additional Funding and Expands Board of Directors
2. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
3. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
4. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
5. Endexx Secures Exclusive World Wide Rights for Medical Marijuana Dispensing Technology
6. BioMotiv Secures $46 Million in Funding
7. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
8. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
9. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
10. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
11. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology:
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):